Gene expression profiling of human mesenchymal stem cells derived from bone marrow during expansion and osteoblast differentiation.
Kulterer B, Friedl G, Jandrositz A, Sanchez-Cabo F, Prokesch A, Paar C, Scheideler M, Windhager R, Preisegger KH, Trajanoski Z. · 2007
Read Gene expression profiling of human mesenchymal stem cells derived from bone marrow during expansion and osteoblast differentiation. by Kulterer B, Friedl G, Jandrositz A, Sanchez-Cabo F, Prokesch A, Paar C, Scheideler M, Windhager R, Preisegger KH, Trajanoski Z. (2007) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc1829400.txt.
Introduction
Kulterer, Trajanoski and co-authors tracked gene activity in human bone marrow stem cells in 2007. These mesenchymal stem cells can become bone-forming osteoblasts, which makes them promising for healing large bone defects. They are rare in marrow, so clinics must grow them outside the body first, raising fears the cells drift.
The team built custom gene chips with 30,000 elements to profile the cells during long growth and bone differentiation. Expanded cells kept their bone-forming ability, their surface marker pattern, and stable expression profiles. During differentiation they passed through three phases: growth, matrix maturation, and mineralization. Three genes stood out for follow-up work: ID4, CRYAB, and SORT1. The profile offers a check that lab-grown cells stay true to type.
Catalog record
| CREATOR | Kulterer B, Friedl G, Jandrositz A, Sanchez-Cabo F, Prokesch A, Paar C, Scheideler M, Windhager R, Preisegger KH, Trajanoski Z. |
|---|---|
| YEAR | 2007 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 56 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Gene expression profiling of human mesenchymal stem cells derived from bone marrow during expansion and osteoblast differentiation By Birgit Kulterer, Gerald Friedl, Anita Jandrositz, Fatima Sanchez-Cabo, Andreas Prokesch, Christine Paar, Marcel Scheideler, Reinhard Windhager, Karl-Heinz Preisegger, Zlatko Trajanoski Published in: BMC Genomics DOI: 10.1186/1471-2164-8-70 ABSTRACT Abstract Background Human mesenchymal stem cells (MSC) with the capacity to differentiate into osteoblasts provide potential for the development of novel treatment strategies, such as improved healing of large bone defects. However, their low frequency in bone marrow necessitate ex vivo expansion for further clinical application. In this study we asked if MSC are developing in an aberrant or unwanted way during ex vivo long-term cultivation and if artificial cultivation conditions exert any influence on their stem cell maintenance. To address this question we first developed human oligonucleotide microarrays with 30.000 elements and then performed large-scale expression profiling of long-term expanded MSC and MSC during differentiation into osteoblasts. Results The results showed that MSC did not alter their osteogenic differentiation capacity, surface marker profile, and the expression profiles of MSC during expansion. Microarray analysis of MSC during osteogenic differentiation identified three candidate genes for further examination and functional analysis: ID4, CRYAB, and SORT1. Additionally, we were able to reconstruct the three developmental phases during osteoblast differentiation: proliferation, matrix maturation, and mineralization, and illustrate the activation of the SMAD signaling pathways by TGF-β2 and BMPs. Conclusion With a variety of assays we could show that MSC represent a cell population which can be expanded for therapeutic applications. BACKGROUND In recent years mesenchymal stem cells (MSC) have generated a great deal of interest as a potential source for cell-based therapeutic strategies. Human MSC are easy to isolate from small aspirate of bone marrow via their adherence ability. These cells readily generate single-cell-derived colonies that can be highly expanded and differentiated into a variety of cell types, such as osteoblasts [1,2], adipocytes [3], myocytes [4], astrocytes and neurons [5,6]. Further, human MSC can improve cardiac function after infarction [7,8] or symptoms of bone and cartilage defects [9-13], as well as neurodegenerative diseases such as Alzheimer's [14-16]. Their efficiency in multiple types of cellular therapeutic strategies has been demonstrated, including applications in treating children with osteogenesis imperfecta [17], hematopoietic recovery [18], and bone tissue regeneration [19,20]. Also first preclinical trails are in progress to test their capacity and toxicity in applications for human treatment [21]. One great advantage of MSC is that these cells may be directly obtained from individual patients, thereby eliminating the complications associated with immune rejection of allogenic tissue and infectious diseases. However, for cell therapies MSC have to be expanded and/or manipulated to obtain a sufficient amount of cells that can be subsequently used for treatment. Despite growing experience and knowledge concerning human MSC and their use in cell-based strategies, the molecular mechanisms that govern MSC self-renewal, expansion and multilineage differentiation are not well understood and remain an active area of investigation. In this study we asked if human MSC are developing in an aberrant or unwanted way during ex vivo long-term cultivation and if cultivation conditions exert any influence on their stem cell maintenance. To address this question systematically and comprehensively we first developed human oligonucleotide microarrays with 30.000 elements and then performed large-scale expression profiling of long-term expanded MSC isolated from clinically relevant samples. We monitored these cells during their expansion ex vivo with respect to proliferation kinetics, surface marker profile and differentiation potential. Finally we analyzed the gene expression profiles of MSC during osteogenic differentiation. Our results showed that expansion of MSC does not result in substantial genetic and morphological aberrations. We illustrated for the first time in a human model the three main stages of osteogenic development, and we could show the diverse regulation of the SMAD pathways by TGF-β2 and BMPs. RESULTS Human MSC maintain their undifferentiated phenotype during long-term expansion The results of the ex vivo long-term expansion experiments showed that the undifferentiated phenotype of MSCs is maintained with respect to differentiation potential, surface marker profile and gene expression profiles. At confluence of 75–85% the cultivated cells were detached and flow cytometry analysis were performed to verify the purity of the cell population without any contaminations, such as haematopoietic cells. Following surface marker profile were detected: CD44+, CD90+, CD73+, CD105+, CD166+, CD11b-, CD34-, CD45-, CD117-, HLA DR-. For the subsequent experiments MSCs were expanded until the end of the tenth passage. At the end of each passage the cells were analyzed by flow cytometry and a cell aliquot was seeded out for testing their differentiation ability. Proliferation kinetics and differentiation potential The growth kinetics of five donors was investigated from the primary culture through the tenth passage, corresponding to approximately 26 cell doublings. For recalculating the starting number of MSC in the MNC fraction, CFU assays were performed and the MSC frequency was determined. Primary cultures reached their first confluence from around 80% in about 2 weeks and about 10 cell doublings. During the following passages the proliferation rate slowed down. During the whole expansion period – starting with passage two until passage ten – in every passage the osteogenic differentiation ability was tested. The osteogenic differentiation was confirmed by Alizarin Red S staining and Alkaline Phosphatase assay. Throughout this examination period differentiation ability into osteoblasts was observed in low passages (passage 2, after 12 cell doublings) as well as in a higher passage (passage 10, after 26 cell doublings), (Figure 1). MSC expanded to approximately 26 cell doublings were able to differentiate into adipocytes (Figure 1). [Figure: Upper panel: Osteogenic differentiation of MSC after passage 2 (A, B) and passage 10 (C, D). Alizarin Red S staining and Alkaline phosphatase assay were performed after 21 days of osteogenic induction (d21).100× magnification. Middle Panel: Morphological alterations during osteogenesis determined by microscopy on the day of induction (d0), day 4, 7, 14 and 21 after induction. All pictures are shown in 100× magnification. Lower Panel: Adipogenic differentiation of MSC in passage 10 characterized by Oil red O staining; (A) MSC not induced, undifferentiated; (B) MSC 21 days after induction with adipogenic medium 100× magnification.] Surface marker profile After the cultivation of MSC from the mononuclear cell fraction (passage 0) and at the end of each individual passage, the MSC were analyzed by flow cytometry to monitor the surface marker profile during their ex vivo expansion. Each investigated passage depicted homogenous cell population demonstrating that MSC did not alter their physical and morphological properties during high grade ex vivo expansion under the culture conditions tested [see Additional file 1]. In addition to the examination of the surface marker profile, we also performed Real-time RT-PCR Sybr™ Green I assays for stem cell specific genes. The examined stem cell markers, CD44, CD73, CD166, CD105, CD90 and STRO1 showed stable expression level during the whole expansion period proving the results obtained by FACS analyses. As expected, CD34, CD45 and TERT could not be detected on any examined time point [see Additional file 2]. Large-scale gene expression profiling of MSC during ex vivo expansion In order to monitor the molecular events that govern the ex vivo expansion of undifferentiated MSC we performed large-scale gene expression profiling using oligonucleotide microarrays with 29952 elements (ArrayExpress, accession numbers